TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11471481
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care management by pharmacists in the intervention group.
Study: 9429994
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg (multiple doses)
Study: 9429994
Drug: Acetaminophen 300
Normalized name: acetaminophen 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 300 mg plus codeine phosphate 30 mg (control)
Study: 3479296
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of 300 mg ofloxacin
Study: 3479296
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form of 300 mg ofloxacin
Study: 3479296
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral solution and tablet form of 300 mg ofloxacin
Study: 24743712
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR 300 mg/d vs 600 mg/d
Study: 20453723
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (standard decompressive laminectomy)
Study: 18476982
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg q.d. as add-on to metformin therapy or as monotherapy
Study: 18476982
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg q.d. as monotherapy
Study: 16669963
Drug: Bisacodyl, 10
Normalized name: Bisacodyl, 10 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl, 10 mg once daily
Study: 3459738
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis immediately
Study: 3459738
Drug: Oral prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis 6 weeks after baseline
Study: 30956141
Drug: Attention-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention-based training (ABT) program, four sessions (4 h/session) over 7 weeks, practice target of 20 min twice-daily
Study: 29468642
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml ropivacaine
Study: 29468642
Drug: 8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 ml isotonic saline
Study: 22854412
Drug: High-antioxidant diet
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-antioxidant diet (5 servings of vegetables and 2 servings of fruit daily; n = 46)
Study: 22854412
Drug: Low-antioxidant diet
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-antioxidant diet (≤2 servings of vegetables and 1 serving of fruit daily; n = 91)
Study: 15919283
Drug: Low-dose anticoagulation
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose anticoagulation (target INR range 1.8 to 2.8 for aortic valve replacement and 2.5 to 3.5 for mitral or double valve replacement)
Study: 15919283
Drug: Conventional-dose anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose anticoagulation (target INR range 2.5 to 4.5 for all heart valve prostheses)
Study: 9818597
Drug: Combined topical-intracameral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical-intracameral anesthesia (1% lidocaine)
Study: 9818597
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (2% lidocaine hydrochloride) alone
Study: 24849736
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation with 26 vitamins and minerals tablet
Study: 23873823
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) 300 μg every 2 weeks starting on Day 28 after HCT
Study: 23873823
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) plus intravenous (i.v.) iron 200 mg on Days 28, 42, and 56
Study: 23873823
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) plus intravenous (i.v.) iron
Study: 23873823
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (DA) administration
Study: 23873823
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) iron administration
Study: 21726411
Drug: Metformin/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/Placebo
Study: 21726411
Drug: Insulin Aspart/NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Aspart/NPH Insulin with Metformin/Placebo
Study: 21726411
Drug: Insulin Aspart/NPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin Aspart/NPH Insulin with Rosiglitazone/Placebo
Study: 19562990
Drug: Procalcitonin (PCT)
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin (PCT) at a threshold of 0.5 ng/mL
Study: 17206671
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus 1 mg/g (1 g ointment twice a day)
Study: 15502061
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) - 250 microg
Study: 15502061
Drug: Ultrasound-assisted femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted femoral nerve block (FNB) - 40 mL of 0.5% ropivacaine, 5 microg/mL of epinephrine, and 75 microg of clonidine
Study: 9785066
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia combined with intercostal blockade (T7-T11) using 0.45% bupivacaine and 0.6% phenol
Study: 9785066
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia alone
Study: 8162986
Drug: ICI-204,219 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI-204,219 (20 mg)
Study: 28646809
Drug: Fascial Distortion
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fascial Distortion Model (FDM) treatment
Study: 28646809
Drug: NDMG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NDMG treatment (control)
Study: 23965206
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (15 mg/kg bolus before incision, followed by 15 mg/kg continuous infusion until skin closure)
Study: 21075773
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (ICD) only therapy
Study: 8440429
Drug: Polidocanol 1%
Normalized name: POLIDOCANOL 1% INJ,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol 1% + adrenaline 1:10,000 injection
Study: 3734514
Drug: Naftidrofuryl (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftidrofuryl (200 mg t.i.d.)
Study: 18657672
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/d for 3 days before surgery
Study: 13678426
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (control group) attending hospital or practice based anticoagulant clinics.
Study: 7697849
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n = 31)
Study: 24277815
Drug: Sex hormone
Normalized name: Sex hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone binding globulin
Study: 24277815
Drug: Endogenous sex
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous sex steroid levels
Study: 24277815
Drug: Hormone concentrations
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone concentrations
Study: 19565542
Drug: T-614 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 50 mg/day for 24 weeks
Study: 19565542
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 10 mg/week for 4 weeks and 15 mg/week for 20 weeks
Study: 19565542
Drug: T-614 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 25 mg/day for 4 weeks and 50 mg/day for 20 weeks
Study: 19565542
Drug: T-614 therapy
Normalized name: BCMA-CS1 cCAR T cell therapy
DrugBank: CAR BCMA-CS1 (DB17313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-614 therapy groups
Study: 16397282
Drug: Otamixaban (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (various intravenous doses)
Study: 11109976
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraception (ethinylestradiol plus desogestrel) for 21 days each month for 12 months
Study: 11109976
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraception (ethinylestradiol plus desogestrel) plus spironolactone daily for 12 months
Study: 8371916
Drug: PhXA41 (0.006%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (0.006% concentration, 60 micrograms/ml) administered once daily
Study: 8371916
Drug: PhXA41 (0.006%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (0.006% concentration, 60 micrograms/ml) administered twice daily
Study: 8371916
Drug: PhXA41 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PhXA41 (both dosing regimens)
Study: 20392866
Drug: Metformin for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin for 10 weeks
Study: 15948994
Drug: Corticosteroid ointment
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid ointment regimen
Study: 10561192
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) alone
Study: 10561192
Drug: Sequential interleukin-3
Normalized name: interleukin-3
DrugBank: Muplestim (DB12431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential interleukin-3 (IL-3) and GM-CSF
Study: 1908478
Drug: hMG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: hMG plus GnRH agonists (Group III)
Study: 26869087
Drug: Iron +
Normalized name: Celebrate Iron + C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron + DHA/EPA combination
Study: 22286978
Drug: Cefaclor formulation
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor formulation 1 (250 mg)
Study: 22286978
Drug: Cefaclor formulation
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor formulation 2 (250 mg)
Study: 20418301
Drug: Gabapentin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (15 mg/kg preoperatively, 5 mg/kg 3 times per day for 5 days postoperatively)
Study: 17554473
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml paté
Study: 17554473
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml egg white
Study: 17554473
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml omelette
Study: 17554473
Drug: 3 ml
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml radiolabeled omelette
Study: 9834957
Drug: Slow‐dissolving formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow‐dissolving formulation
Study: 9834957
Drug: Medium‐dissolving formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium‐dissolving formulation
Study: 9834957
Drug: Fast‐dissolving formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast‐dissolving formulation
Study: 9834957
Drug: Inderal 80
Normalized name: Inderal 80mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inderal 80 mg
Study: 2750531
Drug: 15 U/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 U/m2/week of GH by daily subcutaneous injections for a mean of 0.82 years
Study: 2750531
Drug: 30 U/m2/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 U/m2/week of GH by daily subcutaneous injections for a mean of 0.92 years
Study: 789083
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (adjusted every two weeks to maintain serum level between 0.7 and 1.0 mmol/1)
Study: 28846009
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg omega‐3 fatty acids plus 400 mg vitamin E
Study: 26324672
Drug: ARB therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB therapy (telmisartan)
Study: 26324672
Drug: Non-ARB standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ARB standard therapy
Study: 25168268
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg tabalumab Q4W
Study: 25168268
Drug: 60/120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60/120 mg tabalumab Q4W
Study: 25168268
Drug: 60/120/60 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60/120/60 mg tabalumab Q4W
Study: 22361261
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily for 6 weeks)
Study: 12356283
Drug: Desmopressin (0.396
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.396 microg administered intravenously as a bolus injection)
Study: 12356283
Drug: Lithium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium treatment (period preceding the 6th study day)
Study: 10197827
Drug: Methylphenidate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate therapy
Study: 7191299
Drug: Bay g
Normalized name: ALCOHOL 70 L in 100 L TOPICAL GEL [Victoria Bay Gel Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bay g 5421 (acarbose)
Study: 23572075
Drug: Amitriptyline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (25 mg/d, twice daily for 28 days)
Study: 23572075
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 28 days)
Study: 21980828
Drug: Suplatast tosilate
Normalized name: Edoxaban Tosylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suplatast tosilate (100 mg orally 3 times a day for 2 years)
Study: 21980828
Drug: Fluticasone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone (100 pg inhaled twice a day for 2 years)
Study: 27893087
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care plus 2 years of home‐based occupational therapy
Study: 22823871
Drug: α(1)-blockade (prazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: α(1)-blockade (prazosin, 1 mg/20 kg body weight)
Study: 20595648
Drug: Milled flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milled flaxseed (FXS, n = 13; 32 g/d)
Study: 20595648
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FXO, n = 12; 13 g/d)
Study: 17592102
Drug: Rosiglitazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (2 mg/d)
Study: 12149202
Drug: ADE (cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADE (cytarabine 100 mg/m(2)/d by 7‐day infusion, daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) daily for 3 days)
Study: 12149202
Drug: ADEP (daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADEP (daunorubicin 40 mg/m(2) and etoposide 60 mg/m(2) for 3 days with PSC‐833, 2.8 mg/kg over 2 hours, and then 10 mg/kg/d by 3‐day infusion)
Study: 10084159
Drug: Tegretol CR
Normalized name: Tegretol
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tegretol CR 200 (commercially available controlled-release carbamazepine preparation)
Study: 2111251
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac potassium three times daily for 7 days
Study: 2111251
Drug: 20 mg/day
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/day piroxicam for 7 days
Study: 6963332
Drug: Aspirin (ASA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (ASA), 600 mg, p.o., twice daily for 2 years
Study: 30688523
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with 5‐fluorouracil and oxaliplatin (FOLFOX)
Study: 25938131
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium nitrite 0.5% cream
Study: 25938131
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium nitrite 1.0% cream
Study: 25938131
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium nitrite 1.5% cream
Study: 25938131
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium nitrite 1.8% cream
Study: 25938131
Drug: Topical sodium
Normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sodium nitrite 2.0% cream
Study: 21967073
Drug: Individual virtual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual virtual reality exposure therapy
Study: 17502577
Drug: Otamixaban (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (highest dose)
Study: 17502577
Drug: Otamixaban (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otamixaban (doses 1 to 5)
Study: 17290435
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to approximately 1600 mT (twice)
Study: 14981398
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with protease inhibitor (PI) early
Study: 14981398
Drug: Combination without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination without protease inhibitor (PI)
Study: 14981398
Drug: Monotherapy (monoRx)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (monoRx) early
Study: 14981398
Drug: Monotherapy (monoRx)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (monoRx) late
Study: 14981398
Drug: Combination without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination without protease inhibitor (PI) late
Study: 14981398
Drug: Combination with
Normalized name: Iron in combination with folic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination with protease inhibitor (PI) late
Study: 8769693
Drug: No IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IFN (standard chemotherapy: busulphan or hydroxyurea)
Study: 1732125
Drug: Naloxone infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusions (0.2 micrograms.kg‐1.min‐1)
Study: 11668421
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin certoparin (8000 antifactor Xa U b.i.d.)
Study: 11668421
Drug: Adjusted-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose intravenous unfractionated heparin (UFH)
Study: 9835755
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms of oral clonidine
Study: 31511563
Drug: Psychoactive compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoactive compounds (CANDO platform predictions)
Study: 29061968
Drug: Olodaterol 5 µg
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 µg QD via Respimat®
Study: 29061968
Drug: Formoterol 12 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 µg BID
Study: 24386960
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection (50 U injected intracutaneously into 6-20 sites)
Study: 14723752
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg by mouth followed in two days by vaginal then oral misoprostol (Aberdeen regimen)
Study: 10355844
Drug: Pyruvate supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyruvate supplementation (6 g/d)
Study: 7721404
Drug: Irbesartan 10
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irbesartan 10 mg
Study: 2201664
Drug: Oral L-Dopa
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral L-Dopa
Study: 7030443
Drug: Chlorpromazine plus
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine plus high dose propranolol
Study: 19112224
Drug: Iodixanol (Visipaque)
Normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodixanol (Visipaque) 50 mL
Study: 19112224
Drug: Iohexol (Omnipaque)
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol (Omnipaque) 50 mL
Study: 8285510
Drug: Multichannel cochlear
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multichannel cochlear implants
Study: 19034471
Drug: 50 mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mug misoprostol intravaginally every 4 h to a maximum of five doses